Hazlett, Burt & Watson
HALO icon

Hazlett, Burt & Watson’s Halozyme HALO Stock Holding History

Hazlett, Burt & Watson’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4K Hold
40
– – ﹤0.01% 800
2026
Q2 		$3K Hold
40
– – ﹤0.01% 812
2026
Q1 		$3K Buy
+40
New +$2.82K ﹤0.01% 821

Other funds holding HALO

Boston Partners
Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Stephens Investment Management Group
Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Hazlett, Burt & Watson's HALO Position: Q3 2026 in Review

Hazlett, Burt & Watson held its Halozyme (HALO) position steady in Q3 2026 at 40 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #800.

Hazlett, Burt & Watson first reported a position in HALO in Q1 2026 and has held it in 3 quarters since. 456 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • Hazlett, Burt & Watson held 40 shares of Halozyme worth $4K as of Q3 2026.
  • Hazlett, Burt & Watson left its Halozyme share count unchanged in Q3 2026.
  • Halozyme made up ﹤0.01% of Hazlett, Burt & Watson's portfolio in Q3 2026, its #800 holding.
  • Hazlett, Burt & Watson first reported a position in Halozyme in Q1 2026 and has held it in 3 quarters since.
  • 456 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q3 2026, filed 4 Nov 2026.